Vaccine trials to start in response to Marburg virus outbreak
Rwanda will start clinical trials of experimental vaccines and treatments for Marburg virus in the next few weeks, its health minister announced following news of an outbreak in the country.
Marburg virus disease is highly virulent and causes haemorrhagic fever, with a fatality ratio of up to 88%.
The country’s first outbreak has so far killed 11 people and cases of the virus have been reported in seven districts.
The World Health Organization (WHO) says it is mobilising expertise and outbreak response tools to help reinforce the control measures being rolled out to curb the virus.
“We’re rapidly setting all the critical outbreak response aspects in motion to support Rwanda halt the spread of this virus swiftly and effectively,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “With the country’s already robust public health emergency response system, WHO is collaborating closely with the national authorities to provide the needed support to further enhance the ongoing efforts.”
WHO also hosted a teleconference involving Rwandan scientists and members of the Marburg virus vaccine consortium (MARVAC), a group of companies, non-profit organisations and researchers.
Is there a Marburg vaccine?
As yet there is no approved vaccine for Marburg. Four vaccine candidates have been evaluated for potential use in trials by WHO.
A vaccine developed by the Sabin Vaccine Institute is the only one to have data from early-stage human trials showing it is safe and led to an immune response. The Institute is currently testing the vaccine in an ongoing Phase II clinical trial in Uganda.
Scientists at the University of Oxford in the UK launched a Phase I clinical trial to test its own ChAdOx1 Marburg vaccine in July, while another is under development by the International Aids Vaccine Initiative in New York City.
As part of the response, Gilead Sciences has revealed plans to donate about 5,000 vials of its antiviral drug remdesivir, originally developed to treat Ebola, to the Rwanda Medical Supply for emergency use.
